Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
Hepatitis B virus (HBV) is the leading cause of chronic liver disease and liver-related death worldwide, with the majority of these cases occurring in areas of Africa and Asia where HBV prevalence is high. Many of the countries that are affected by hepatitis B are also affected by a high HIV burden, leading to frequent HIV/HBV co-infection. The consequences of co-infection, including increased liver-related morbidity and mortality, increased hepatitis B viral replication, immune reconstitution to HBV in the setting of antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in regions with expanding antiretroviral programmes. Little data, however, are available on HIV/HBV co-infection from regions with high chronic hepatitis B prevalence. This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted.
Hoffmann
Christopher J
CJ
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. choffmann@jhmi.edu
Thio
Chloe L
CL
D000349:Africa / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001208:Asia / Q000453:epidemiology; D002908:Chronic Disease; D015897:Comorbidity; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D006509:Hepatitis B / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D006801:Humans; D015995:Prevalence; D019562:Viral Load; D014779:Virus Replication